We continuously promote the improvement of a comprehensive quality management system throughout the entire product lifecycle to ensure compliance with cGMP standards and regulatory development trends in China, the United States, and Europe. The Company prioritizes quality, strengthens the segmented contract manufacturing management system for biological products, and achieves collaborative operations across multiple production sites and enterprises by dividing the production process into multiple stages. We have successfully passed the supervisory inspection by the NMPA, the European Union Qualified Person audit and audits conducted by our international partners. Through “standardized division of labor and refined management”, we enhance quality control, drive regulatory innovation, prioritize patients’ benefits, and improve supply chain security and drug accessibility.
